Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

References

• TLV - The Dental and Pharmaceutical Benefits Agency. The review of antidepressants. TLV [Internet]. 2008. Available from: www.tlv.se/Upload/Genomgangen/review-antidepressants.pdf
   Google Scholar
• Lee S, Jeong J, Kwak Y, et al. Depression research: where are we now? Mol Brain. 2010;3:8.
   PubMed Web of Science ®Google Scholar
• Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–392.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults (Updated Edition). Leicester (UK): The British Psychological Society & The Royal College of Psychiatrists; 2010.
   Google Scholar
• Hamalainen J, Isometsa E, Sihvo S, et al. Treatment of major depressive disorder in the Finnish general population. Depress Anxiety. 2009;26(11):1049–1059.
   PubMed Web of Science ®Google Scholar
• Saarni SI, Harkanen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15(8):1403–1414.
   PubMed Web of Science ®Google Scholar
• Soini E, Hallinen T. Cost-utility of agomelatine, venlafaxine and placebo in the treatment of major depressive disorder (MDD) in Finland - economic modelling study using representative population data. Value Health. 2009;12:A359.
   Web of Science ®Google Scholar
• Gould R, Grönlund H, Korpiluoma R, et al. Miksi masennus vie eläkkeelle? Eläketurvakeskuksen raportteja 2007:1. Helsinki: Hakapaino Oy; 2007.
   Google Scholar
• Fimea drug statistics year 2014. 2014 [updated 2014]. Available from: http://raportit.nam.fi/raportit/kulutus/kv_laakekulutus.pdf
   Google Scholar
• National Institute of Mental Health. 2015. Available from: http://www.nimh.nih.gov/health/topics/depression/index.shtml#part_145399
   Google Scholar
• Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J ClinPsychiatry. 2010;71 Suppl E1:e08.
   PubMedGoogle Scholar
• McCracken C, Dalgard OS, Ayuso-Mateos JL, et al. Health service use by adults with depression: community survey in five European countries. Evidence from the ODIN study 5. Br J Psychiatry. 2006;189:161–167.
   PubMed Web of Science ®Google Scholar
• Chisholm D, Diehr P, Knapp M, et al. Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry. 2003;183:121–131.
   PubMed Web of Science ®Google Scholar
• Brignone M, Diamand F, Painchault C, et al. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016;32(2):351–366.
   PubMed Web of Science ®Google Scholar
• Haji Ali AH, Karnon J, Gray J. A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources. Pharmacoeconomics. 2012;30(6):461–482.
   PubMed Web of Science ®Google Scholar
• Choi S-E, Brignone M, Cho SJ, et al. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2016. doi:10.1586/14737167.2016.1128830 [Epub ahead of print]
   Web of Science ®Google Scholar
• Suomalaisen Lääkäriseura Duodecimin ja Suomen Psykiatriyhdistys ry:n asettama työryhmä. Depressio Käypä Hoito -Suositus. Helsinki: Duodecim; 2013.
   Google Scholar
• Heo M, Murphy CF, Meyers BS. Relationship between the Hamilton depression rating scale and the Montgomery-Asberg depression rating scale in depressed elderly: a meta-analysis. Am J Geriatr Psychiatry. 2007;15(10):899–905.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J PsychiatrRes. 2004;38(6):577–582.
   Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–482.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G. The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol. 2013;23(8):814–821.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242.
   PubMed Web of Science ®Google Scholar
• Limosin F, Loze J-Y, Zylberman-Bouhassira M, et al. The course of depressive illness in general practice. Can J Psychiatry. 2004;49(2):119–123.
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408–1416.
   PubMed Web of Science ®Google Scholar
• Cipriani A, La FT, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010;1:CD006117.
   PubMedGoogle Scholar
• Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J ClinPsychiatry. 2009;70(8):1128–1137.
   PubMed Web of Science ®Google Scholar
• Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266.
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51(9):753–761.
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106–113.
   PubMedGoogle Scholar
• Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60(7):791–798.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911–932.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Information Centre [Internet]. [ cited 2015 May]. Available from: http://www.laaketietokeskus.fi/en
   Google Scholar
• Finnish Medicines Tarrif [Internet]. [ cited 2014 Feb]. Available from: http://www.kela.fi/web/en/reimbursements-for-medicine-expences
   Google Scholar
• Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011. Helsinki: THL; 2014.
   Google Scholar
• Painchault C, Brignone M, Lamy FX, Diamand F, Saragoussi D Economic Burden of Major Depressive Disorder (Mdd) in Five European Countries: Description of Resource use by Health State. Value Health. 2014;17(7):A465.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;2:CD006532.
   PubMed Web of Science ®Google Scholar
• Hallinen T, Soini E. The impact of the pharmaceutical pricing system on cost-effectiveness results: finnish analysis. Open Pharmacoeconom Health Econ J. 2011;3:6–10.
   Google Scholar
• Annemans L, Brignone M, Druais S, et al. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium. Pharmacoeconomics. 2014;32(5):479–493.
   PubMed Web of Science ®Google Scholar
• Mencacci C, Di SG, Katz P, et al. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy. Clinicoecon Outcomes Res. 2013;5:87–99.
   PubMedGoogle Scholar
• Beck A, Crain AL, Solberg LI, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9(4):305–311.
   PubMed Web of Science ®Google Scholar
• Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22(3):153–162.
   PubMed Web of Science ®Google Scholar
• Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry. 2003;183:514–519.
   PubMed Web of Science ®Google Scholar